Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Understanding the material basis of adaptive evolution has been a central goal in biology dating back to at least the time of ...

Connections made via apical synapses seemed to be strengthened by movement information more than those made via basal ...

A study has constructed an unprecedented pangenome map of wild and cultivated rice, and decoded the genetic architecture and ...

With OpenAI's recent introduction of Codex CLI and new foundation models, the company hearkens us back to 2021 when its Codex ...